基于ALU的游离DNA在结直肠癌中的诊断和预后意义：一项系统评价和荟萃分析

Diagnostic and prognostic significance of ALU-based cell-free DNA in colorectal cancer: a systematic review and meta-analysis.

作者信息

Taghizadeh-Teymorloei Mohammad, Alizadeh Leila, Matin Somaieh, Jafari-Koshki Tohid, Karimi Abbas

机构信息

Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Gastroenterology and Liver Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

出版信息

Front Oncol. 2024 Aug 7;14:1398062. doi: 10.3389/fonc.2024.1398062. eCollection 2024.

DOI:10.3389/fonc.2024.1398062

PMID:39169935

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11335620/

Abstract

INTRODUCTION

Colorectal cancer (CRC) is a major global health concern. This study aimed to investigate the role of ALU-based cell-free DNA (cfDNA) in the diagnosis and prognosis of CRC.

METHODS

We selected relevant literature from PubMed, Scopus, Web of Science, EMBASE, and Science Direct databases based on strict inclusion and exclusion criteria. 17 eligible studies were included in the final analysis (13 studies for diagnostic and 4 studies for prognostic meta-analysis). The search covered relevant publications up to July 1, 2024.

RESULTS

The pooled sensitivity, specificity, and diagnostic odds ratios (DOR) of ALU-based cfDNA in CRC diagnosis were 0.81 (95% CI= [0.70, 0.89]), 0.90 (95% CI= [0.70, 0.96]), and 40.58 (95% CI= [17.87, 92.19]), respectively. The area under the ROC curve was 0.92 (95% CI= [0.89, 0.94]). Patients with higher concentrations of plasma/serum ALU-based cfDNA had poorer overall survival (OS) (pooled hazard ratio = 2.33 ([95% CI= [1.80, 3.03]).

CONCLUSION

The current evidence supports the utility of circulating ALU as a promising non-invasive diagnostic and prognostic tool for CRC. Furthermore, as a potential biomarker, ALU-based cfDNA could play a significant role in clinical application.

CLINICAL IMPLICATIONS

The evidence suggests that circulating ALU-based cell-free DNA (cfDNA) holds promise as a non-invasive diagnostic and prognostic tool for colorectal cancer, potentially enhancing clinical decision-making.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, identifier PROSPERO (CRD42023486369).

摘要

引言

结直肠癌（CRC）是全球主要的健康问题。本研究旨在探讨基于ALU的游离DNA（cfDNA）在CRC诊断和预后中的作用。

方法

我们根据严格的纳入和排除标准，从PubMed、Scopus、Web of Science、EMBASE和Science Direct数据库中筛选相关文献。最终分析纳入了17项符合条件的研究（13项用于诊断分析，4项用于预后的荟萃分析）。检索涵盖截至2024年7月1日的相关出版物。

结果

基于ALU的cfDNA在CRC诊断中的合并敏感性、特异性和诊断比值比（DOR）分别为0.81（95%CI = [0.70, 0.89]）、0.90（95%CI = [0.70, 0.96]）和40.58（95%CI = [17.87, 92.19]）。ROC曲线下面积为0.92（95%CI = [0.89, 0.94]）。血浆/血清中基于ALU的cfDNA浓度较高的患者总生存期（OS）较差（合并风险比 = 2.33 [95%CI = [1.80, 3.03]）。